A primer pair, method and kit for detecting Cryptococcus neoformans
By designing primer pairs and polymerase chain reaction PCR detection methods for Cryptococcal neoformans, the problems of low sensitivity and time-consuming of existing Cryptococcal test methods are solved, and the rapid and accurate detection of Cryptococcal neoformans is achieved, and targeted support treatment plan development.
Patent Information
- Application Number
- CN202311314779.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-10-11
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2043-10-11
AI Technical Summary
The existing Cryptococcus detection methods have low sensitivity, long time or inability to distinguish Cryptococcus species, resulting in inaccurate diagnosis of Cryptococcus neogenesis and affecting the formulation of treatment plans.
Design primer pairs for specific gene fragments of Cryptococcal neoformans, perform fluorescence quantitative detection through polymerase chain reaction PCR, accurately identify Cryptococcal neoformans, and provide kits containing primer pairs to improve detection accuracy.
It realizes rapid and accurate detection of Cryptococcus neoformans, improves the sensitivity and specificity of diagnosis, supports the formulation of targeted treatment plans, and reduces the diagnosis time and misdiagnosis rate.
Smart Images

Figure CN117467791B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of fungal pathogen detection, and particularly relates to a primer pair, a method and a kit for detecting Cryptococcus neoformans. Background Art
[0002] There are two main pathogenic cryptococci: Cryptococcus neoformans and Cryptococcus gattii. Among them, Cryptococcus neoformans mainly infects immunosuppressed people. In recent years, with the widespread use of immunosuppressants after organ suppression and the increase in the base of people with immune diseases such as AIDS, the number of cases of Cryptococcus neoformans infection has increased year by year, showing a high morbidity and mortality rate, becoming the focus of clinical attention. Since cryptococcal infection is usually an invisible infection, the symptoms in the early clinical stage are not typical and it is easy to be misdiagnosed as a bacterial infection. Therefore, pathogen detection has become an important basis for the diagnosis and treatment of cryptococcal disease.
[0003] Commonly used methods for detecting Cryptococcus include ink staining, culture identification, and antigen detection. Among them, the ink staining method has a low sensitivity; the culture identification method is time-consuming and not conducive to rapid clinical diagnosis; the antigen detection method can quickly detect Cryptococcus but cannot further distinguish the types of Cryptococcus, making it impossible for physicians to specify more targeted treatment plans during diagnosis. Therefore, how to accurately detect and identify Cryptococcus neoformans is a technical problem that needs to be solved urgently. Summary of the invention
[0004] The present invention provides a primer pair, a method, a kit for detecting Cryptococcus neoformans and the use of the primer pair in detecting Cryptococcus neoformans. By designing a corresponding primer pair for a specific gene fragment of Cryptococcus neoformans, Cryptococcus neoformans can be accurately detected, thereby helping to improve the accuracy of Cryptococcus neoformans detection.
[0005] In a first aspect, the present application provides a primer pair for detecting Cryptococcus neoformans, the primer pair comprising a forward primer and a reverse primer, the nucleotide sequence of the forward primer is shown in Seq ID No.1, and the nucleotide sequence of the reverse primer is shown in Seq ID No.2.
[0006] In some embodiments, the primer pair is used to identify the nucleotide sequence shown in Seq ID No. 3 in the Cryptococcus neoformans.
[0007] In a second aspect, a method for detecting Cryptococcus neoformans is provided, the method comprising: obtaining a template DNA of a sample to be tested; amplifying the template DNA by polymerase chain reaction (PCR) to obtain an amplification result, wherein the PCR reactants include the primer pair and fluorescent dye in any embodiment of the first aspect; and judging whether the detection result of Cryptococcus neoformans in the sample to be tested is positive or negative based on the amplification result.
[0008] In some embodiments, judging whether the detection result of Cryptococcus neoformans in the sample to be tested is positive or negative based on the amplification result includes: when the sample to be tested has a logarithmic increase in fluorescence and a cycle threshold value Ct is less than or equal to 30.0 in the amplification result, determining that the detection result of Cryptococcus neoformans in the sample to be tested is positive; or when the sample to be tested has no logarithmic increase in fluorescence in the amplification result, determining that the detection result of Cryptococcus neoformans in the sample to be tested is negative; or when the sample to be tested has a logarithmic increase in fluorescence and a cycle threshold value Ct is greater than 30.0 in the amplification result, determining that the detection result of Cryptococcus neoformans in the sample to be tested is negative.
[0009] In a third aspect, a kit for detecting Cryptococcus neoformans is provided, wherein the kit comprises the primer pair in any embodiment of the present application.
[0010] In some embodiments, the kit further comprises: a buffer, a template DNA, a DNA polymerase and / or deoxynucleoside triphosphate dNTPs.
[0011] In a fourth aspect, a primer pair according to any one of the embodiments of the present application is provided for use in detecting Cryptococcus neoformans. BRIEF DESCRIPTION OF THE DRAWINGS
[0012] Figure 1 This is a schematic flow chart of a method for detecting Cryptococcus neoformans according to an embodiment of the present application.
[0013] Figure 2 This is a specific amplification curve of Cryptococcus neoformans according to an embodiment of the present application. DETAILED DESCRIPTION
[0014] The technical solution of the present application is further introduced below in conjunction with specific embodiments.
[0015] "Scope" disclosed in the present application is limited in the form of lower limit and upper limit, and a given range is limited by selecting a lower limit and an upper limit, and the selected lower limit and upper limit define the boundary of a special range. The scope limited in this way can be including end values or not including end values, and can be arbitrarily combined, that is, any lower limit can be combined with any upper limit to form a scope. For example, if the scope of 60-120 and 80-110 is listed for a specific parameter, it is understood that the scope of 60-110 and 80-120 is also expected. In addition, if the minimum range values 1 and 2 are listed, and if the maximum range values 3, 4 and 5 are listed, the following scope can be all expected: 1-3, 1-4, 1-5, 2-3, 2-4 and 2-5. In the present application, unless otherwise specified, the numerical range "ab" represents the abbreviation of any real number combination between a and b, wherein a and b are real numbers. For example, the numerical range "0-5" means that all real numbers between "0-5" are listed in this document, and "0-5" is just an abbreviation of these numerical combinations. In addition, when a parameter is expressed as an integer ≥ 2, it is equivalent to disclosing that the parameter is, for example, an integer of 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, etc.
[0016] In the description of the present application, the terms “first”, “second”, “third”, etc. are used for descriptive purposes only and should not be understood as indicating or implying relative importance.
[0017] If there is no special explanation, the "include" and "comprising" mentioned in this application are open-ended or closed-ended. For example, the "include" and "comprising" may mean that other components not listed may also be included or only the listed components may be included or only the listed components may be included.
[0018] If not specifically stated, in this application, the term "or" is inclusive. For example, the phrase "A or B" means "A, B, or both A and B". More specifically, any of the following conditions satisfies the condition "A or B": A is true (or exists) and B is false (or does not exist); A is false (or does not exist) and B is true (or exists); or both A and B are true (or exist).
[0019] Unless otherwise specified, all embodiments and optional embodiments of the present application can be combined with each other to form a new technical solution.
[0020] Cryptococcus neoformans is a type of cryptococcus that can cause serious infections in humans, mainly causing cryptococcal disease in people with low cellular immunity, such as those who have undergone organ transplantation, long-term hormone use, and AIDS patients. Cryptococcus neoformans usually invades the human body through razors or damaged skin and mucous membranes, and spreads through the bloodstream to the brain, bones, and skin. According to research statistics, 80% of cases of cryptococcal disease caused by Cryptococcus neoformans damage the central nervous system and cause chronic meningitis. In addition, it may also cause pneumonia and other infections, such as invading lymph nodes, bones, skin and other parts, causing inflammation or abscesses.
[0021] At present, the clinical detection methods for Cryptococcus neoformans mainly rely on ink smears and fungal culture, with the detection of pathogens as the basis for diagnosis. In terms of rapid diagnosis, although direct smear ink staining is simple, it is relatively difficult to observe under the microscope, so the positive detection rate is low. Foreign literature reports that even in the case of multiple consecutive examinations, the positive rate is only 53%-56%. At the same time, there are certain false positives, and it is difficult to count cryptococci. Traditional fungal culture generally takes several days. Although the culture positive rate can reach more than 90%, the long cycle delays diagnosis. In addition, there are relatively rapid antigen and antibody tests. Although they can quickly detect cryptococci, they cannot further distinguish the types of cryptococci. There is a situation where Cryptococcus neoformans is mistakenly reported as Cryptococcus gattii, misleading the direction of diagnosis.
[0022] In view of this, the present application provides a primer pair for detecting Cryptococcus neoformans, and the polymerase chain reaction (PCR) based on the primer pair can accurately and quickly detect Cryptococcus neoformans.
[0023] First, the embodiment of the present application provides a primer pair for detecting Cryptococcus neoformans.
[0024] The primer pair includes a forward primer and a reverse primer. The nucleotide sequence of the forward primer is shown in Seq ID No.1, and the nucleotide sequence of the reverse primer is shown in Seq ID No.2.
[0025] Specifically, the inventors used bioinformatics methods to compare the entire genomes of bacteria such as Cryptococcus neoformans, Cryptococcus gattii, Staphylococcus aureus, Klebsiella pneumoniae, Escherichia coli, and Candida albicans, not limited to a single coding gene, but to find differential sites at the entire genome level, thereby designing a primer pair with nucleotide sequences as shown in Seq ID No. 1 and Seq ID No. 2. The primer pair can specifically identify the nucleotide sequence shown in SeqID No. 3 that only Cryptococcus neoformans has. Using this primer pair for Cryptococcus neoformans detection can efficiently and accurately detect Cryptococcus neoformans.
[0026] The nucleotide sequence of the forward primer is specifically:
[0027] GTACCACAGCCCCGATACAG.
[0028] The nucleotide sequence of the reverse primer is specifically:
[0029] TGGATACACAAGGTGAGCAAC.
[0030] The primer pair is used to identify the nucleotide sequence in Cryptococcus neoformans as shown in Seq ID No. 3. In other words, the primer pair designed for Cryptococcus neoformans can specifically identify the nucleotide sequence in Cryptococcus neoformans as shown in Seq ID No. 3.
[0031] The above primer pairs have obvious advantages of high sensitivity and strong specificity in detecting and identifying Cryptococcus neoformans.
[0032] The embodiment of the present application also provides a method 100 for detecting Cryptococcus neoformans.
[0033] Figure 1 1 is a schematic flow chart of a method 100 for detecting Cryptococcus neoformans according to an embodiment of the present application. Figure 1 As shown, the method 100 includes:
[0034] S101, obtaining template DNA of the sample to be tested.
[0035] S102, amplifying the template DNA by polymerase chain reaction (PCR) to obtain an amplification result, wherein the PCR reactants include the primer pair and fluorescent dye in any embodiment of the present application.
[0036] S103, judging whether the detection result of Cryptococcus neoformans in the sample to be tested is positive or negative according to the amplification result.
[0037] Specifically, the fluorescent dye in S102 can dye DNA without binding to a single-stranded DNA. It does not emit light in a free state, and only emits light when incorporated into a double-stranded DNA. Exemplary, SYBR Green dye. In a PCR amplification reaction, the intensity of the fluorescent signal can be positively correlated with the number of PCR products as the PCR-specific product is exponentially amplified. Thus, the above-mentioned primer-probe combination provided in the present application can effectively detect whether Cryptococcus neoformans is present in the sample to be tested through fluorescent quantitative PCR.
[0038] Optionally, the sample to be tested includes blood, body fluid, and / or lung tissue.
[0039] Optionally, in S103, judging whether the detection result of Cryptococcus neoformans in the sample to be tested is positive or negative according to the amplification result includes:
[0040] When the fluorescence logarithm increases and the Ct is less than or equal to 30.0, the sample to be tested is judged to be positive for Cryptococcus neoformans; or
[0041] When there is no increase in the fluorescence logarithm, the sample to be tested is judged to be negative for Cryptococcus neoformans; or
[0042] When the fluorescence logarithm increases and the Ct is greater than 30.0, it is determined that Cryptococcus neoformans in the sample to be tested is negative.
[0043] The embodiments of the present application also provide a kit for detecting Cryptococcus neoformans, which comprises the primer pair in any embodiment of the present application.
[0044] Optionally, the kit further comprises: a buffer, a template DNA, deoxynucleotide triphosphate dNTP and / or a DNA polymerase.
[0045] Optionally, the kit further comprises MgCl2.
[0046] The kit provided in the embodiments of the present application can accurately and quickly detect Cryptococcus neoformans, and has the advantages of simple operation, short detection time, and strong adaptability. It can meet the needs of rapid clinical diagnosis, provide a reliable basis for the designation of treatment plans, and save precious time for the treatment of the disease.
[0047] In addition, an embodiment of the present application also provides a use of a primer pair as in any of the above embodiments in detecting Cryptococcus neoformans.
[0048] Next, the specific steps of the detection method 100 provided in the present application are further introduced. It should be understood that the following examples are only for illustrating the implementation of the identification method of the present application, wherein the specific reagent dosage or instrument usage can be adjusted as needed, and does not constitute a limitation on the examples of the present application.
[0049] Example 1: Extraction of genomic DNA
[0050] 1. Test materials: samples to be tested
[0051] The samples to be tested described in the present application include but are not limited to blood, body fluids or lung tissues.
[0052] 2. Main reagents and instruments
[0053] DNA was extracted using the yeast gene extraction kit from Tiangen Company; the synthesis of primers and probes was completed by Bioengineering Co., Ltd.; Quanti Fast SYBR® Green PCR Kit was purchased from Qiagen Company; and the fluorescence quantitative PCR instrument was purchased from Roche Company.
[0054] 3. Experimental Methods
[0055] DNA was extracted according to the instructions of the DNA extraction kit, and the DNA content in the sample was determined using a spectrophotometer, and the OD260 / OD280 ratio was determined. The sample to be tested provided in this example contained Cryptococcus neoformans and Cryptococcus gattii.
[0056] Example 2: PCR amplification reaction
[0057] 2.1 PCR detection of Cryptococcus
[0058] 1. Test Materials
[0059] Genomic DNA. The specific PCR reaction system is shown in Table 1.
[0060] 2. Main reagents and instruments
[0061] Table 1: Real-time fluorescence PCR reaction system 1 (25 μL)
[0062]
[0063] 3. Experimental Methods
[0064] In this example, the PCR amplification reaction was performed using the Quanti Fast SYBR® Green PCR Kit from Qiagen. The PCR amplification process can be found in the product manual of the kit.
[0065] In this example, the nucleotide sequence of the forward primer is shown in Seq ID No. 1, and the nucleotide sequence of the reverse primer is shown in Seq ID No. 2.
[0066] In this embodiment, the amplification conditions of the PCR reaction are: 95 o C pre-denaturation for 5 min; 95 o C 10s, 68 o C for 60 s and 45 cycles to obtain the amplification results.
[0067] 4. Analyze and judge the amplification results
[0068] Figure 2 This is the amplification curve of Cryptococcus neoformans obtained through the above operation in the example of the present application. Figure 2 In the amplification curve, the ordinate is the relative fluorescence unit (RFU) and the abscissa is the number of amplification cycles.
[0069] like Figure 2As shown, in the test results of the sample to be tested, Cryptococcus neoformans was specifically amplified, with a fluorescence logarithmic increase and a corresponding amplification curve, and Ct≤30.0. However, the Cryptococcus gattii in the parallel experiment had no specific amplification curve. This shows that the primer pair has good specificity for Cryptococcus neoformans and can specifically identify the nucleotide sequence in Cryptococcus neoformans as shown in Seq ID No. 3, that is, it can accurately identify Cryptococcus neoformans in the sample to be tested. And the three amplification curves of Cryptococcus neoformans all have almost the same fluorescence logarithmic increase, indicating that the method of detecting Cryptococcus neoformans using this primer pair has good repeatability. In addition, Figure 2 The template DNA concentration in the assay was 0.1 ng / μL, and there was still a good fluorescence logarithmic response after fluorescence PCR, indicating that the method for detecting Cryptococcus neoformans using this primer pair has excellent sensitivity.
[0070] Therefore, the primer pair provided in the present application can accurately and efficiently detect Cryptococcus neoformans.
[0071] In summary, the primer pair provided in the present application has good specificity for Cryptococcus neoformans, and the method for detecting Cryptococcus neoformans using the primer pair has good repeatability and sensitivity. The detection kit containing the primer pair provided in the present application is used to detect Cryptococcus neoformans, which is simple to operate and has reliable and accurate results, and can help physicians to quickly diagnose diseases infected by cryptococci, which is conducive to formulating appropriate treatment methods and reducing drug abuse.
[0072] In the description of this specification, the description with reference to the terms "one embodiment", "an implementation", "some embodiments", "illustrative implementation", "example", "specific example", or "some examples" means that the specific features, structures, materials or characteristics described in conjunction with the implementation or example are included in at least one implementation or example of the present application. In this specification, the schematic representation of the above terms does not necessarily refer to the same implementation or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more implementations or examples in a suitable manner.
[0073] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present application, rather than to limit it. Although the present application has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present application.
Claims
1. A primer pair for detecting Cryptococcus neoformans, It is characterized in that The primer pair includes a forward primer and a reverse primer, the nucleotide sequence of the forward primer is shown in Seq ID No.1, and the nucleotide sequence of the reverse primer is shown in Seq ID No.2; the primer pair is used to identify the nucleotide sequence shown in Seq ID No.3 in the Cryptococcus neoformans; the primer pair is used to detect the Cryptococcus neoformans in a sample including the Cryptococcus neoformans and Cryptococcus gattii.
2. A kit for detecting Cryptococcus neoformans, It is characterized in that The kit comprises the primer pair as claimed in claim 1.
3. The kit according to claim 2, It is characterized in that The kit further comprises: a buffer, a template DNA, a DNA polymerase and / or deoxynucleoside triphosphate dNTP.
4. Use of the primer pair according to claim 1 in preparing a kit for detecting Cryptococcus neoformans.
